<DOC>
	<DOCNO>NCT00791154</DOCNO>
	<brief_summary>This trial title `` A Phase 1b/2 trial AMG 479 AMG 102 Platinum-Based Chemotherapy First-Line Treatment Extensive Stage Small-Cell Lung Cancer ( SCLC ) . '' Part 1 , phase 1b portion study , multicenter , open-label investigation identify safe dose level either AMG 102 AMG 479 combination etoposide plus cisplatin carboplatin subject previously untreated extensive stage SCLC . Part 2 , phase 2 portion study , multicenter , double-blind , 3-arm investigation evaluate overall survival either AMG 102 AMG 479 combination platinum-based chemotherapy .</brief_summary>
	<brief_title>QUILT-2.013 : A Trial AMG 479 AMG 102 Combination With Platinum-based Chemotherapy First-Line Treatment Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Inclusion Criteria Histologically cytologically confirm SCLC Extensive disease , define least one following : No limited disease ( ie , disease confine ipsilateral hemithorax , safely encompass within tolerable radiation field ) Extrathoracic metastases Malignant pericardial pleural effusion Contralateral hilar adenopathy Measurable nonmeasurable disease , define modified RECIST Eastern Cooperative Oncology Group ( ECOG ) status 0 1 ≥18 year old Life expectancy ( therapy ) ≥3 month Adequate hematologic , hepatic , coagulation , renal , metabolic function Diabetes , present , must control , glycosylated hemoglobin ( HbA1C ) ≤ 8 % fast glucose level ≤160 mg/dL Key Exclusion Criteria Prior chemotherapy , chemoradiation , investigational agent SCLC Prior radiotherapy &gt; 25 % bone marrow Symptomatic untreated central nervous system metastasis ( exception ) Currently previously treat biologic , immunologic therapy SCLC Current serious nonhealing wound ulcer History prior concurrent malignancy ( exception ) Thorombosis vascular ischemic event within last 12 month DVT , PE , TIA MI Any clinically significant medical condition cancer ( eg , cardiovascular disease COPD ) , could interfere safe delivery study treatment risk toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Extensive disease</keyword>
	<keyword>Extrathoracic metasasis</keyword>
	<keyword>Malignant pericardial effusion</keyword>
	<keyword>Malignant pleural effusion</keyword>
	<keyword>Contralateral hilar adenopathy</keyword>
</DOC>